The Finnish Cancer Registry as Follow-Up Source of a Large Trial Cohort

Authors

  • Pasi Korhonen From the Orion Pharma, Department of Biostatistics and Data Management, Espoo, Finland (P. Korhonen), Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland (P. Korhonen, N. Malila, J. Virtamo), Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland (N. Malila, E. Pukkala, L. Teppo) and the National Cancer Institute, Bethesda, MD, USA (D. Albanes)
  • Nea Malila From the Orion Pharma, Department of Biostatistics and Data Management, Espoo, Finland (P. Korhonen), Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland (P. Korhonen, N. Malila, J. Virtamo), Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland (N. Malila, E. Pukkala, L. Teppo) and the National Cancer Institute, Bethesda, MD, USA (D. Albanes)
  • Eero Pukkala From the Orion Pharma, Department of Biostatistics and Data Management, Espoo, Finland (P. Korhonen), Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland (P. Korhonen, N. Malila, J. Virtamo), Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland (N. Malila, E. Pukkala, L. Teppo) and the National Cancer Institute, Bethesda, MD, USA (D. Albanes)
  • Lyly Teppo From the Orion Pharma, Department of Biostatistics and Data Management, Espoo, Finland (P. Korhonen), Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland (P. Korhonen, N. Malila, J. Virtamo), Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland (N. Malila, E. Pukkala, L. Teppo) and the National Cancer Institute, Bethesda, MD, USA (D. Albanes)
  • Demetrius Albanes From the Orion Pharma, Department of Biostatistics and Data Management, Espoo, Finland (P. Korhonen), Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland (P. Korhonen, N. Malila, J. Virtamo), Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland (N. Malila, E. Pukkala, L. Teppo) and the National Cancer Institute, Bethesda, MD, USA (D. Albanes)
  • Jarmo Virtamo From the Orion Pharma, Department of Biostatistics and Data Management, Espoo, Finland (P. Korhonen), Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland (P. Korhonen, N. Malila, J. Virtamo), Finnish Cancer Registry, Institute for Statistical and Epidemiological Cancer Research, Helsinki, Finland (N. Malila, E. Pukkala, L. Teppo) and the National Cancer Institute, Bethesda, MD, USA (D. Albanes)

DOI:

https://doi.org/10.1080/028418602760169442

Abstract

We evaluated the accuracy and time to reporting of cancer diagnoses obtained through the Finnish Cancer Registry (FCR) for the Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) Study in 1985-1997. In the ATBC Study suspect neoplasms were centrally reviewed through medical records and pathology specimens. The FCR data were compared against the reviewed data for 3600 cancers of eight sites. For most sites, 95% of the cases were reported to the FCR within 0.9 years with longer delays for lung and pancreatic cancers. Ninety-six percent of all FCR cases received the same primary site diagnosis in the ATBC review, and in 1.4% no malignancy was found. Conversely, 97% of cancers ascertained in the ATBC review had the same primary site in the FCR and 0.8% were unknown to the R egistry. The accuracy of the FCR data is high but the delay in case notification should be considered in epidemiological studies.

Downloads

Download data is not yet available.

Downloads

Published

2002-01-01

How to Cite

Korhonen, P. ., Malila, N., Pukkala, E. ., Teppo, L. ., Albanes, D. ., & Virtamo, J. . (2002). The Finnish Cancer Registry as Follow-Up Source of a Large Trial Cohort. Acta Oncologica, 41(4), 381–388. https://doi.org/10.1080/028418602760169442

Issue

Vol. 41 No. 4 (2002): Acta Oncologica

Section

Articles